Bobak R. Azamian - Net Worth and Insider Trading

Bobak R. Azamian Net Worth

The estimated net worth of Bobak R. Azamian is at least $39 Million dollars as of 2024-11-06. Bobak R. Azamian is the President/CEO and Board Chair of Tarsus Pharmaceuticals Inc and owns about 856,562 shares of Tarsus Pharmaceuticals Inc (TARS) stock worth over $39 Million. Details can be seen in Bobak R. Azamian's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Bobak R. Azamian has not made any transactions after 2024-03-18 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Bobak R. Azamian

Bobak R. Azamian Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Bobak R. Azamian owns 1 companies in total, including Tarsus Pharmaceuticals Inc (TARS) .

Click here to see the complete history of Bobak R. Azamian’s form 4 insider trades.

Insider Ownership Summary of Bobak R. Azamian

Ticker	Comapny	Transaction Date	Type of Owner
TARS	Tarsus Pharmaceuticals Inc	2024-03-18	director & 10 percent owner & President and CEO

Bobak R. Azamian Latest Holdings Summary

Bobak R. Azamian currently owns a total of 1 stock. Bobak R. Azamian owns 856,562 shares of Tarsus Pharmaceuticals Inc (TARS) as of March 18, 2024, with a value of $39 Million.

Latest Holdings of Bobak R. Azamian

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
TARS	Tarsus Pharmaceuticals Inc	2024-03-18	856,562	45.66	39,110,621

Holding Weightings of Bobak R. Azamian

Bobak R. Azamian Form 4 Trading Tracker

According to the SEC Form 4 filings, Bobak R. Azamian has made a total of 46 transactions in Tarsus Pharmaceuticals Inc (TARS) over the past 5 years, including 0 buys and 46 sells. The most-recent trade in Tarsus Pharmaceuticals Inc is the sale of 10,415 shares on March 18, 2024, which brought Bobak R. Azamian around $318,699.

Insider Trading History of Bobak R. Azamian

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Bobak R. Azamian Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Bobak R. Azamian Ownership Network

Ownership Network List of Bobak R. Azamian

No Data

Ownership Network Relation of Bobak R. Azamian

Bobak R. Azamian Owned Company Details

What does Tarsus Pharmaceuticals Inc do?

Who are the key executives at Tarsus Pharmaceuticals Inc?

Bobak R. Azamian is the director & 10 percent owner & President and CEO of Tarsus Pharmaceuticals Inc. Other key executives at Tarsus Pharmaceuticals Inc include See Remarks Jeffrey S Farrow , Chief Human Resources Officer Dianne C. Whitfield , and General Counsel Bryan Wahl .

Tarsus Pharmaceuticals Inc (TARS) Insider Trades Summary

Over the past 18 months, Bobak R. Azamian made 14 insider transaction in Tarsus Pharmaceuticals Inc (TARS) with a net sale of 240,415. Other recent insider transactions involving Tarsus Pharmaceuticals Inc (TARS) include a net sale of 11,909 shares made by Aziz Mottiwala , a net sale of 12,792 shares made by Bryan Wahl , and a net sale of 12,669 shares made by Dianne C. Whitfield .

In summary, during the past 3 months, insiders sold 35,000 shares of Tarsus Pharmaceuticals Inc (TARS) in total and bought 0 shares, with a net sale of 35,000 shares. During the past 18 months, 331,965 shares of Tarsus Pharmaceuticals Inc (TARS) were sold and 10,506 shares were bought by its insiders, resulting in a net sale of 321,459 shares.

Tarsus Pharmaceuticals Inc (TARS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Tarsus Pharmaceuticals Inc Insider Transactions

No Available Data

Bobak R. Azamian Mailing Address

Above is the net worth, insider trading, and ownership report for Bobak R. Azamian. You might contact Bobak R. Azamian via mailing address: 15440 Laguna Canyon Road, Suite 160, Irvine Ca 92618.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.